Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K8NR
|
|||
| Former ID |
DCL000425
|
|||
| Drug Name |
AMG 386
|
|||
| Synonyms |
7440-23-5; Natrium; Sodium-23; Sodio; Sodium metal; Sodio [Spanish]; Sodium (liquid alloy); UNII-9NEZ333N27; HSDB 687; EINECS 231-132-9; UN1428; UNII-23J3BHR95O; Sodium, dry stick; 9NEZ333N27; MFCD00085307; Sodium, 998%, oiled sticks, wrapped in aluminium foil; monosodium; sodium atom; mono sodium; mono-sodium; Sodium, CP; SodiuR4733m hydride, CP; AC1NSENP; ACMC-1BKTZ; Sodium, ACS reagent, dry; 11Na; EC 231-132-9; AC1Q1W6R; SODIUM, LARGE PIECES; Sodium hydride, dry, 95%; NAH 80; HSDB 745; CTK2H7876; CHEBI:26708; Oravescent fentanyl; R3487; PT-15; R4930
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 3 | [1], [2] | |
| Neuropathic pain [ICD-11: 8E43.0] | Phase 3 | [3] | ||
| Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9] | Phase 2 | [4] | ||
| Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Discontinued in Phase 2 | [5] | ||
| Sexual dysfunction [ICD-11: HA00-HA01] | Preclinical | [6] | ||
| Company |
Amgen
|
|||
| Structure |
 |
Download2D MOL |
||
| Canonical SMILES |
[Na]
|
|||
| InChI |
1S/Na
|
|||
| InChIKey |
KEAYESYHFKHZAL-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 7440-23-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
5326610, 8146756, 10534514, 15170295, 15237733, 24845275, 24848128, 24853383, 24854694, 24855921, 24857014, 24857016, 24868737, 24871915, 24881721, 24886151, 24886235, 24888697, 33088985, 39384005, 50046431, 50074094, 53788965, 57362018, 57647078, 57648086, 57652275, 57652326, 77905220, 83620210, 88826695, 114148349, 117376386, 125809647, 126675963, 131325865, 134339053, 134339153, 134339154, 134339155, 134339359, 134339385, 134339536, 134339884, 134340144, 134987874, 134988506, 137102243, 137156482, 139072878
|
|||
| ChEBI ID |
CHEBI:26708
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8414). | |||
| REF 2 | ClinicalTrials.gov (NCT01281254) TRINOVA-2: Trebananib in Ovarian Cancer-2. U.S. National Institutes of Health. | |||
| REF 3 | Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26. | |||
| REF 4 | Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov. 2009 Sep;8(9):733-50. | |||
| REF 5 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027884) | |||
| REF 6 | Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60. | |||
| REF 7 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | |||
| REF 8 | Clinical pipeline report, company report or official report of Roche (2009). | |||
| REF 9 | Clinical targeting of the TNF and TNFR superfamilies.Nat Rev Drug Discov.2013 Feb;12(2):147-68. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.